HDAC1 controls CIP2A transcription in human colorectal cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Colorectal cancer (CRC) is a significant global health concern.
• Overexpression of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) is implicated in various cancers, including CRC.
• Reduced activity of the oncosuppressor phosphatase PP2A is observed in many cancers.

Purpose of the Study:

• To investigate the efficacy of the HDAC inhibitor (S)-2 against colorectal cancer cells.
• To elucidate the molecular mechanisms underlying the anti-cancer effects of (S)-2, focusing on the HDAC1-CIP2A-PP2A axis.
• To evaluate the in vitro and in vivo anti-tumor potential of (S)-2.

Main Methods:

• In vitro studies using CRC HCT116 cells and other CRC cell lines.
• In vivo studies involving mice xenografts to assess tumor growth inhibition.
• Analysis of gene and protein expression, including HDAC1, CIP2A, PP2A, pGSK-3β, β-catenin, c-Myc, and cyclin D1.
• Utilized HDAC inhibitor (S)-2 and specific siRNAs targeting HDAC1.

Main Results:

• HDAC inhibitor (S)-2 effectively induced cell cycle arrest and apoptosis in CRC cells.
• (S)-2 and HDAC1-specific siRNAs downregulated CIP2A transcription in CRC cell lines.
• Re-activation of PP2A phosphatase activity was observed, leading to dephosphorylation of pGSK-3β(ser9).
• Downregulation of β-catenin, c-Myc, and cyclin D1 expression resulted in growth arrest and abrogated Wnt/β-catenin signaling.
• Significant inhibition of tumor growth was observed in vivo in mice xenografts.

Conclusions:

• HDAC1 inhibition by (S)-2 represents a novel therapeutic strategy for colorectal cancer.
• The study provides the first evidence that (S)-2 downregulates CIP2A, unleashes PP2A activity, and induces CRC cell growth arrest and apoptosis.
• (S)-2 demonstrates promising anti-cancer effects both in vitro and in vivo, warranting further clinical investigation.